Spots Global Cancer Trial Database for A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
Official Title: A Randomized Phase I/II Study of BI-505 in Conjunction With High-dose Melphalan and Autologous Stem Cell Transplantation for Multiple Myeloma
Study ID: NCT02756728
Conditions
Study Description
Brief Summary: The purpose of this study is to investigate the safety and efficacy of administering BI-505 in conjunction with high dose melphalan and stem cell transplantation in multiple myeloma patients.
Detailed Description: N/A study is closed
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Perelman School of Medicine/Hospital of the Univ. of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Contact Details
Name: Alfred Garfall, MD
Affiliation: Div of Hema/Onc, Dept.of Med, Perelman Center Advanced Med, Philadelphia PA
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
